The Ambani Succession Plan: Isha, Akash, Anant Join Reliance Board
Reliance ushered in a new era of leadership with Nita Ambani stepping down from the board of directors and making way for her children Isha, Akash, and Anant.
Isha Ambani, Akash Ambani and Anant Ambani are set to be appointed non-executive directors of the oil-to-retail conglomerate, pending an approval by its shareholders. The recommendations came at a board meeting ahead of the company's annual general meeting on Monday.
Mukesh Ambani is the chairman of Reliance Industries Limited (RIL).
The three Ambani scions have been closely involved with and are leading and managing key businesses of Reliance over the last few years including retail, digital services and energy and materials businesses, the company said in a press release.
They also serve on the boards of the key subsidiaries of Reliance.
Though Nita Ambani has resigned from the board of directors, she will continue to attend all board meetings as a permanent invitee so that the company can continue to benefit from her advice, said the release.
"The Board of Directors also accepted the resignation of Nita Ambani from the Board respecting her decision to devote her energies and time to guide and enable Reliance Foundation to make even greater impact for India," it said.
Mukesh Ambani had first spoken of his succession plan in 2021. He had even identified three separate verticals for his three children, with the new energy business going to his youngest son Anant. The telecom and digital business will go to his elder son Akash the retail business to twin sister Isha.
Last year, Mr Ambani made way for Akash to become the chairman of Reliance Jio Infocomm Ltd. However, he still remains the chairman of Jio Platforms, which holds Reliance Jio Infocomm.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.